Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$41.99 - $62.38 $52,277 - $77,663
-1,245 Reduced 96.44%
46 $2,000
Q3 2023

Nov 21, 2023

SELL
$27.8 - $45.35 $367,738 - $599,889
-13,228 Reduced 91.11%
1,291 $56,000
Q2 2023

Aug 22, 2023

BUY
$36.13 - $49.49 $524,571 - $718,545
14,519 New
14,519 $111,000
Q1 2022

Apr 27, 2022

SELL
$75.82 - $150.97 $3.63 Million - $7.22 Million
-47,850 Closed
0 $0
Q4 2021

Feb 18, 2022

BUY
$132.01 - $190.29 $6.32 Million - $9.11 Million
47,850 New
47,850 $7.02 Million
Q2 2021

Aug 26, 2021

SELL
$144.0 - $179.73 $206,784 - $258,092
-1,436 Closed
0 $0
Q1 2021

Apr 28, 2021

SELL
$158.92 - $221.61 $3,496 - $4,875
-22 Reduced 1.51%
1,436 $245,000
Q4 2020

Jan 28, 2021

BUY
$162.05 - $240.27 $3,241 - $4,805
20 Added 1.39%
1,458 $320,000
Q3 2020

Oct 30, 2020

BUY
$113.26 - $167.27 $162,867 - $240,534
1,438 New
1,438 $238,000

Others Institutions Holding MRTX

About Mirati Therapeutics, Inc.


  • Ticker MRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,609,800
  • Description
  • Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...
More about MRTX
Track This Portfolio

Track Comerica Bank Portfolio

Follow Comerica Bank and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Comerica Bank, based on Form 13F filings with the SEC.

News

Stay updated on Comerica Bank with notifications on news.